Is Genmab A/S (GMAB) a Buy, Sell, or Hold?
NASDAQ : GMAB
Genmab A/S
$28.87 USD
-$0.3 (-1.03%)
- Volume
- 1.68M
- Average Volume
- 1.94M
- Market Capitalization
- $17.72B
- P/E Ratio
- 21.74
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $35.43
- Year Low
- $21.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.18
Company Overview
NASDAQ
Jan van de Winkel
Biotechnology
Healthcare
GMAB
2638
DK
USD
Liquidity Metrics
0.94
2.18
2.17
1.29
0.00
Sales & Valuation
$3.72B
1.89
3.13
20.32
1.42
Profitability
$1.54
$963.76M
8.72%
10.99%
14.55%
6.64%
P/E Metrics
21.74
-0.25
-0.25
Analyst Price Target & Rating
$40.00
$43.00
$32.00
3/5
18 Analysts
-27.83%
Financial Health Scores
11.68
6/9
$1.39B
$12.38B
$6.69B
$1.2B
Key Metrics (TTM)
$21.37B
2.27
15.15
2.18
14.55%
8.89%
4.68%
4.98%
$166.83
-1131 days
Company Executives
| Name | Title |
|---|---|
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer |
| Christopher Cozic | Executive Vice President & Chief People Officer |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer |
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer |
| Anthony Pagano | Executive Vice President & Chief Financial Officer |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director |
Poll Results
No votes yet today — be the first to share your view!
About Genmab A/S (NASDAQ:GMAB) Stock
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a ro ... bust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
2026-07-23 16:00:00
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults.
Genmab: Multiple Late-Stage Readouts Ahead
2026-07-22 11:34:18
Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support expectations for a revenue beat and upward guidance revision. The company expects to report topline results from up to five late-stage trials of Epkinly, petosemtamab, and Rina-S.
2026-07-22 08:04:28
Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning futures are already flashing red. Find out which stocks analysts are rushing to upgrade, cut, or cover for the first time before the opening bell.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
2026-07-15 06:22:00
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 4,207 million in the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
2026-07-07 12:15:36
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
2026-07-06 13:59:01
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE FL-1 trial, fixed-duration TEPKINLYR2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete response Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLYR2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).
2026-07-06 13:45:00
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial that evaluated fixed-duration TEPKINLY + R2 compared to standard of care R2. “Follicular.
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
2026-06-30 12:31:46
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
Frequently Asked Questions
-
What is the current Genmab A/S (GMAB) stock price?
-
Genmab A/S(NASDAQ:GMAB) stock price is $28.87 in the last trading session. During the trading session, GMAB stock reached the peak price of $35.43 while $20.995 was the lowest point it dropped to. The percentage change in GMAB stock occurred in the recent session was --1.03% while the dollar amount for the price change in GMAB stock was -$0.3.
-
GMAB's industry and sector of operation?
-
The NASDAQ listed GMAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GMAB?
-
Martine J. van Vugt | Executive Vice President & Chief Strategy Officer
Judith V. Klimovsky | Executive Vice President & Chief Development Officer
Christopher Cozic | Executive Vice President & Chief People Officer
Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer
Rayne Waller | Executive Vice President & Chief Technical Operations Officer -
How many employees does GMAB have?
-
Number of GMAB employees currently stands at 2638. GMAB operates from Carl Jacobsens Vej 30, Copenhagen, CD 2500, DK.
-
Link for GMAB official website?
-
Official Website of GMAB is: https://www.genmab.com
-
How do I contact GMAB?
-
GMAB could be contacted at phone #45 70 20 27 28 and can also be accessed through its website. GMAB operates from Carl Jacobsens Vej 30, Copenhagen, CD 2500, DK.
-
How many shares of GMAB are traded daily?
-
The average number of GMAB shares traded daily for last 3 months was 1.94M.
-
What is the market cap of GMAB currently?
-
The market value of GMAB currently stands at $17.72B with its latest stock price at $28.87